First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors

BACKGROUND: ASP3026 is a second-generation anaplastic lymphoma kinase (ALK) inhibitor that has potent in vitro activity against crizotinib-resistant ALK-positive tumors. This open-label, multicenter, first-in-human phase I study (NCT01284192) assessed the safety, pharmacokinetic profile, and antitum...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Hematol Oncol
Autores principales: Li, Tianhong, LoRusso, Patricia, Maitland, Michael L., Ou, Sai-Hong Ignatius, Bahceci, Erkut, Ball, Howard A., Park, Jung Wook, Yuen, Geoffrey, Tolcher, Anthony
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4786998/
https://ncbi.nlm.nih.gov/pubmed/26966027
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-016-0254-5
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares